Table 2.
Clinical response to first-line taxane-based therapy
| First-line therapy | CR, n (%) | PR, n (%) | SD, n (%) | PD, n (%) | Response unknown, n (%) |
|---|---|---|---|---|---|
| All (n = 74) | 20 (27.0) | 16 (21.6) | 4 (5.4) | 15 (20.3) | 19 (25.7) |
| Docetaxel (n = 39) | 6 (15.4) | 9 (23.1) | 4 (10.3) | 10 (25.6) | 10 (25.6) |
| Paclitaxel (n = 35) | 14 (40.0) | 7 (20.0) | 0 (0) | 5 (14.3) | 9 (25.7) |
| Monotherapy (n = 30) | 6 (20.0) | 6 (20.0) | 1 (3.3) | 7 (23.3) | 10 (33.3) |
| Combination therapy (n = 44) | 14 (31.8) | 10 (22.7) | 3 (6.8) | 8 (18.2) | 9 (20.5) |
CR = Complete response, PR = partial response, SD = stable disease; PD = progressive disease.